The effect of age on blood pressure response by 4‐week treatment perindopril: A pooled sex‐specific analysis of the EUROPA, PROGRESS, and ADVANCE trials

Abstract Previous studies showed that postmenopausal women are more likely to have poorly controlled hypertension than men of the same age. Whether this is caused by inadequate treatment or poor response to antihypertensive agents remains unknown. The aim of this study is to analyze treatment respon...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Michelle M. Schreuder, Katrina M. Mirabito Colafella, Eric Boersma, Jasper J. Brugts, Jeanine E. Roeters van Lennep, Jorie Versmissen
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	Therapeutics. Pharmacology RM1-950 Public aspects of medicine RA1-1270
Acceso en línea:	https://doaj.org/article/4506fd6d6db3457ebd46d5da9c2e858f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4506fd6d6db3457ebd46d5da9c2e858f
record_format	dspace
spelling	oai:doaj.org-article:4506fd6d6db3457ebd46d5da9c2e858f2021-11-19T17:51:34ZThe effect of age on blood pressure response by 4‐week treatment perindopril: A pooled sex‐specific analysis of the EUROPA, PROGRESS, and ADVANCE trials1752-80621752-805410.1111/cts.13076https://doaj.org/article/4506fd6d6db3457ebd46d5da9c2e858f2021-11-01T00:00:00Zhttps://doi.org/10.1111/cts.13076https://doaj.org/toc/1752-8054https://doaj.org/toc/1752-8062Abstract Previous studies showed that postmenopausal women are more likely to have poorly controlled hypertension than men of the same age. Whether this is caused by inadequate treatment or poor response to antihypertensive agents remains unknown. The aim of this study is to analyze treatment response to the most potent renin angiotensin aldosterone system (RAAS) inhibitor perindopril in different age categories in women and men. Individual patient data were used from the combined European Trial on Reduction of Cardiac Events With Perindopril (EUROPA), Perindopril Protection Against Recurrent Stroke Study (PROGRESS), and Action in Diabetes and Vascular disease: Preterax and Diamicron‐MR Controlled Evaluation (ADVANCE) trials, which include patients with vascular disease (n = 29,463). We studied the relative and absolute changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP) during a 4‐week run‐in phase in which all patients were treated with the perindopril‐based treatment in different age categories. In total, 8366 women and 21,097 men were included in the analysis. Women greater than 65 years of age showed a significantly smaller blood pressure reduction after perindopril treatment (2.8 mmHg [95% confidence interval {CI} = 0.1–5.5] less reduction compared to women ≤45 years, p = 0.039). In men, the SBP reduction after perindopril in patients greater than 55–65 and greater than 65 years was lower compared to the age category less than or equal to 45 years (adjusted mean difference >55–65: 2.8 mmHg [95% CI = 1.8–3.7], p < 0.001, >65: 3.7 mmHg [95% CI = 2.7–4.7], p < 0.001). A trend of less blood pressure reduction was seen with ageing in both men and women (p < 0.001). To conclude, we observed that in both women and men the perindopril leads to less SBP reduction with increasing age, whereas the DBP reduction increases with age. More research is needed to determine whether it would be beneficial to use age‐adjusted perindopril dosages.Michelle M. SchreuderKatrina M. Mirabito ColafellaEric BoersmaJasper J. BrugtsJeanine E. Roeters van LennepJorie VersmissenWileyarticleTherapeutics. PharmacologyRM1-950Public aspects of medicineRA1-1270ENClinical and Translational Science, Vol 14, Iss 6, Pp 2193-2199 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Therapeutics. Pharmacology RM1-950 Public aspects of medicine RA1-1270
spellingShingle	Therapeutics. Pharmacology RM1-950 Public aspects of medicine RA1-1270 Michelle M. Schreuder Katrina M. Mirabito Colafella Eric Boersma Jasper J. Brugts Jeanine E. Roeters van Lennep Jorie Versmissen The effect of age on blood pressure response by 4‐week treatment perindopril: A pooled sex‐specific analysis of the EUROPA, PROGRESS, and ADVANCE trials
description	Abstract Previous studies showed that postmenopausal women are more likely to have poorly controlled hypertension than men of the same age. Whether this is caused by inadequate treatment or poor response to antihypertensive agents remains unknown. The aim of this study is to analyze treatment response to the most potent renin angiotensin aldosterone system (RAAS) inhibitor perindopril in different age categories in women and men. Individual patient data were used from the combined European Trial on Reduction of Cardiac Events With Perindopril (EUROPA), Perindopril Protection Against Recurrent Stroke Study (PROGRESS), and Action in Diabetes and Vascular disease: Preterax and Diamicron‐MR Controlled Evaluation (ADVANCE) trials, which include patients with vascular disease (n = 29,463). We studied the relative and absolute changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP) during a 4‐week run‐in phase in which all patients were treated with the perindopril‐based treatment in different age categories. In total, 8366 women and 21,097 men were included in the analysis. Women greater than 65 years of age showed a significantly smaller blood pressure reduction after perindopril treatment (2.8 mmHg [95% confidence interval {CI} = 0.1–5.5] less reduction compared to women ≤45 years, p = 0.039). In men, the SBP reduction after perindopril in patients greater than 55–65 and greater than 65 years was lower compared to the age category less than or equal to 45 years (adjusted mean difference >55–65: 2.8 mmHg [95% CI = 1.8–3.7], p < 0.001, >65: 3.7 mmHg [95% CI = 2.7–4.7], p < 0.001). A trend of less blood pressure reduction was seen with ageing in both men and women (p < 0.001). To conclude, we observed that in both women and men the perindopril leads to less SBP reduction with increasing age, whereas the DBP reduction increases with age. More research is needed to determine whether it would be beneficial to use age‐adjusted perindopril dosages.
format	article
author	Michelle M. Schreuder Katrina M. Mirabito Colafella Eric Boersma Jasper J. Brugts Jeanine E. Roeters van Lennep Jorie Versmissen
author_facet	Michelle M. Schreuder Katrina M. Mirabito Colafella Eric Boersma Jasper J. Brugts Jeanine E. Roeters van Lennep Jorie Versmissen
author_sort	Michelle M. Schreuder
title	The effect of age on blood pressure response by 4‐week treatment perindopril: A pooled sex‐specific analysis of the EUROPA, PROGRESS, and ADVANCE trials
title_short	The effect of age on blood pressure response by 4‐week treatment perindopril: A pooled sex‐specific analysis of the EUROPA, PROGRESS, and ADVANCE trials
title_full	The effect of age on blood pressure response by 4‐week treatment perindopril: A pooled sex‐specific analysis of the EUROPA, PROGRESS, and ADVANCE trials
title_fullStr	The effect of age on blood pressure response by 4‐week treatment perindopril: A pooled sex‐specific analysis of the EUROPA, PROGRESS, and ADVANCE trials
title_full_unstemmed	The effect of age on blood pressure response by 4‐week treatment perindopril: A pooled sex‐specific analysis of the EUROPA, PROGRESS, and ADVANCE trials
title_sort	effect of age on blood pressure response by 4‐week treatment perindopril: a pooled sex‐specific analysis of the europa, progress, and advance trials
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/4506fd6d6db3457ebd46d5da9c2e858f
work_keys_str_mv	AT michellemschreuder theeffectofageonbloodpressureresponseby4weektreatmentperindoprilapooledsexspecificanalysisoftheeuropaprogressandadvancetrials AT katrinammirabitocolafella theeffectofageonbloodpressureresponseby4weektreatmentperindoprilapooledsexspecificanalysisoftheeuropaprogressandadvancetrials AT ericboersma theeffectofageonbloodpressureresponseby4weektreatmentperindoprilapooledsexspecificanalysisoftheeuropaprogressandadvancetrials AT jasperjbrugts theeffectofageonbloodpressureresponseby4weektreatmentperindoprilapooledsexspecificanalysisoftheeuropaprogressandadvancetrials AT jeanineeroetersvanlennep theeffectofageonbloodpressureresponseby4weektreatmentperindoprilapooledsexspecificanalysisoftheeuropaprogressandadvancetrials AT jorieversmissen theeffectofageonbloodpressureresponseby4weektreatmentperindoprilapooledsexspecificanalysisoftheeuropaprogressandadvancetrials AT michellemschreuder effectofageonbloodpressureresponseby4weektreatmentperindoprilapooledsexspecificanalysisoftheeuropaprogressandadvancetrials AT katrinammirabitocolafella effectofageonbloodpressureresponseby4weektreatmentperindoprilapooledsexspecificanalysisoftheeuropaprogressandadvancetrials AT ericboersma effectofageonbloodpressureresponseby4weektreatmentperindoprilapooledsexspecificanalysisoftheeuropaprogressandadvancetrials AT jasperjbrugts effectofageonbloodpressureresponseby4weektreatmentperindoprilapooledsexspecificanalysisoftheeuropaprogressandadvancetrials AT jeanineeroetersvanlennep effectofageonbloodpressureresponseby4weektreatmentperindoprilapooledsexspecificanalysisoftheeuropaprogressandadvancetrials AT jorieversmissen effectofageonbloodpressureresponseby4weektreatmentperindoprilapooledsexspecificanalysisoftheeuropaprogressandadvancetrials
_version_	1718420007414661120

The effect of age on blood pressure response by 4‐week treatment perindopril: A pooled sex‐specific analysis of the EUROPA, PROGRESS, and ADVANCE trials

Ejemplares similares